MEAGAN TAYLOR: Open Payments
NPI 1912678897 · DURANGO, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,991 in 72 payments from 14 companies in 2025. Trend: 2023 $33 · 2024 $1,999 · 2025 $1,991
Food & beverage: $1,991
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $643 |
| Ardelyx, Inc. | 9 | $260 |
| Janssen Biotech, Inc. | 6 | $235 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $207 |
| Gilead Sciences, Inc. | 8 | $173 |
| Madrigal Pharmaceuticals | 2 | $149 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $104 |
| GENZYME CORPORATION | 2 | $48 |
| Aimmune Therapeutics, Inc. | 2 | $46 |
| Lilly USA, LLC | 2 | $44 |
Products named: RINVOQ, IBSRELA, TREMFYA, ENTYVIO, REZDIFFRA, SKYRIZI, XIFAXAN, MAVYRET.
Industry payments across CO — which companies pay providers there.
